Figure S5 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer

Figure S5. Immediate dynamic contrast enhanced (DCE) MRI in PDAC6 tumor with MnL4 performed before, at 3 days (1 dose FOLFIRNOX), or at 7 days (2 doses FOLFIRINOX) after the initiation of FOLFIRINOX treatment. Time course of change in normalized signal intensity acquired from DCE images with MnL4 as the probe (0.1 mmol/kg, i.v., n = 4 for each group, data shown as mean value with 95% simultaneous confidence bands as shaded regions). Data are superimposable at each time point measured, indicating no changes in tumor permeability or extracellular volume with FOLFIRINOX treatment.